Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

551 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinoma.
Qiang N, Ao J, Nakamura M, Chiba T, Kusakabe Y, Kaneko T, Kurosugi A, Kogure T, Ma Y, Zhang J, Ogawa K, Kan M, Iwanaga T, Sakuma T, Kanayama K, Kanzaki H, Kojima R, Nakagawa R, Kondo T, Nakamoto S, Muroyama R, Kato J, Mimura N, Ma A, Jin J, Kato N. Qiang N, et al. Among authors: nakagawa r. Int Immunopharmacol. 2023 May;118:110068. doi: 10.1016/j.intimp.2023.110068. Epub 2023 Mar 29. Int Immunopharmacol. 2023. PMID: 37001386
Successful Identification of a Novel Therapeutic Compound for Hepatocellular Carcinoma Through Screening of ADAM9 Inhibitors.
Ogawa K, Chiba T, Nakamura M, Arai J, Zhang J, Ma Y, Qiang NA, Ao J, Yumita S, Ishino T, Kan M, Iwanaga T, Nakagawa M, Fujiwara K, Sakuma T, Kanzaki H, Koroki K, Kusakabe Y, Kobayashi K, Kanogawa N, Kiyono S, Kondo T, Nakagawa R, Ogasawara S, Muroyama R, Nakamoto S, Kanda T, Maruyama H, Kato J, Matsumoto S, Arai T, Motohashi S, Kato N. Ogawa K, et al. Among authors: nakagawa m, nakagawa r. Anticancer Res. 2023 Mar;43(3):1043-1052. doi: 10.21873/anticanres.16249. Anticancer Res. 2023. PMID: 36854524
Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma.
Kanogawa N, Ogasawara S, Maruta S, Iino Y, Obu M, Ishino T, Ogawa K, Yumita S, Iwanaga T, Unozawa H, Nakagawa M, Fujiwara K, Sakuma T, Fujita N, Kojima R, Kanzaki H, Koroki K, Kobayashi K, Inoue M, Kiyono S, Nakamura M, Kondo T, Saito T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Itobayashi E, Koma Y, Azemoto R, Kato J, Kato N. Kanogawa N, et al. Among authors: nakagawa m, nakagawa r. BMC Gastroenterol. 2023 Mar 11;23(1):70. doi: 10.1186/s12876-023-02674-x. BMC Gastroenterol. 2023. PMID: 36906542 Free PMC article.
Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
Yumita S, Ogasawara S, Nakagawa M, Maruta S, Okubo T, Itokawa N, Iino Y, Obu M, Haga Y, Seki A, Kogure T, Ishino T, Ogawa K, Fujiwara K, Iwanaga T, Fujita N, Sakuma T, Kojima R, Kanzaki H, Koroki K, Inoue M, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Itobayashi E, Atsukawa M, Koma Y, Azemoto R, Ito K, Mizumoto H, Kato J, Kato N. Yumita S, et al. Among authors: nakagawa m, nakagawa r. BMC Gastroenterol. 2023 Mar 31;23(1):101. doi: 10.1186/s12876-023-02731-5. BMC Gastroenterol. 2023. PMID: 37003980 Free PMC article.
Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis.
Kanzaki H, Ogasawara S, Okubo T, Itokawa N, Yoshino R, Fujimoto K, Kogure T, Yumita S, Ishino T, Ogawa K, Iwanaga T, Nakagawa M, Fujiwara K, Kojima R, Koroki K, Inoue M, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Itobayashi E, Atsukawa M, Kato J, Kato N. Kanzaki H, et al. Among authors: nakagawa m, nakagawa r. Drugs Real World Outcomes. 2023 Dec;10(4):513-520. doi: 10.1007/s40801-023-00379-x. Epub 2023 Jul 19. Drugs Real World Outcomes. 2023. PMID: 37466822 Free PMC article.
Investigation of risk factors for metachronous recurrence in patients with early gastric adenocarcinoma by miRNA-mRNA integral profiling.
Nagashima A, Okimoto K, Nakagawa R, Akizue N, Matsumura T, Oura H, Kojima R, Goto C, Takahashi S, Horio R, Kurosugi A, Ishikawa T, Shiratori W, Kaneko T, Kanayama K, Ohta Y, Taida T, Saito K, Chiba T, Kato J, Kato N. Nagashima A, et al. Among authors: nakagawa r. Sci Rep. 2023 Nov 11;13(1):19661. doi: 10.1038/s41598-023-47000-3. Sci Rep. 2023. PMID: 37952025 Free PMC article.
Controlling Major Portal Vein Invasion Progression during Lenvatinib Treatment by Carbon-Ion Radiotherapy in Patients with Advanced Hepatocellular Carcinoma.
Yoshida R, Koroki K, Makishima H, Ogasawara S, Ishino T, Ogawa K, Nakagawa M, Fujiwara K, Unozawa H, Iwanaga T, Fujita N, Sakuma T, Kanzaki H, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Saito T, Nakagawa R, Suzuki E, Ooka Y, Nakamoto S, Tawada A, Chiba T, Arai M, Kaneko T, Wakatsuki M, Kato J, Tsuji H, Kato N. Yoshida R, et al. Among authors: nakagawa m, nakagawa r. Case Rep Oncol. 2021 Jul 15;14(2):1103-1110. doi: 10.1159/000517440. eCollection 2021 May-Aug. Case Rep Oncol. 2021. PMID: 38075390 Free PMC article.
Combination of serum human satellite RNA and miR-21-5p levels as a biomarker for pancreatic cancer.
Seimiya T, Suzuki T, Iwata T, Kishikawa T, Sekiba K, Shibata C, Ishigaki K, Fujiwara H, Oyama H, Kanai S, Sato T, Nakai Y, Ishibashi R, Moriyama M, Nakagawa R, Ijichi H, Otsuka M, Koike K. Seimiya T, et al. Among authors: nakagawa r. iScience. 2023 Jan 19;26(2):106021. doi: 10.1016/j.isci.2023.106021. eCollection 2023 Feb 17. iScience. 2023. PMID: 36798431 Free PMC article.
Comprehensive analysis of perioperative hypotension in photodynamic diagnosis-assisted transurethral resection of bladder tumor with 5-aminolevulinic acid.
Nohara T, Takimoto A, Shinzawa R, Kurauchi D, Toriumi R, Nakagawa R, Aoyama S, Kamijima T, Kano H, Naito R, Kadomoto S, Iwamoto H, Yaegashi H, Kawaguchi S, Shigehara K, Izumi K, Mizokami A. Nohara T, et al. Among authors: nakagawa r. Int J Urol. 2024 Apr 30. doi: 10.1111/iju.15477. Online ahead of print. Int J Urol. 2024. PMID: 38687138
551 results